These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11399341)

  • 21. Soluble P-selectin and thrombomodulin-protein C-Protein S pathway in cyanotic congenital heart disease with secondary erythrocytosis.
    Horigome H; Murakami T; Isobe T; Nagasawa T; Matsui A
    Thromb Res; 2003; 112(4):223-7. PubMed ID: 14987915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic-pulmonary shunts in infants and children. Early and late results.
    Lamberti JJ; Carlisle J; Waldman JD; Lodge FA; Kirkpatrick SE; George L; Mathewson JW; Turner SW; Pappelbaum SJ
    J Thorac Cardiovasc Surg; 1984 Jul; 88(1):76-81. PubMed ID: 6204171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surface expression of major membrane glycoproteins on resting and TRAP-activated neonatal platelets.
    Simák J; Holada K; Janota J; Stranák Z
    Pediatr Res; 1999 Oct; 46(4):445-9. PubMed ID: 10509366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity.
    Tarnow I; Michelson AD; Barnard MR; Frelinger AL; Aasted B; Jensen BR; Parving HH; Rossing P; Tarnow L
    Platelets; 2009 Nov; 20(7):513-9. PubMed ID: 19852691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modified Blalock-Taussig shunt: statistical analysis of potential factors influencing shunt outcome.
    Tsai KT; Chang CH; Lin PJ
    J Cardiovasc Surg (Torino); 1996 Apr; 37(2):149-52. PubMed ID: 8675521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of fibrinogen receptor antagonist GR144053F and aurintricarboxylic acid on platelet activation and degranulation.
    Rozalski M; Boncler M; Golanski J; Watala C
    Biochem Pharmacol; 2001 Nov; 62(10):1399-408. PubMed ID: 11709200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and associated factors of renal dysfunction and proteinuria in cyanotic congenital heart disease.
    Hongsawong N; Khamdee P; Silvilairat S; Chartapisak W
    Pediatr Nephrol; 2018 Mar; 33(3):493-501. PubMed ID: 28971258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of blood rheology in patients with cyanotic congenital heart disease using a microchannel array flow analyzer.
    Katayama Y; Horigome H; Murakami T; Takahashi-Igari M; Miyata D; Tanaka K
    Clin Hemorheol Microcirc; 2006; 35(4):499-508. PubMed ID: 17148849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical results of combined palliative procedures for cyanotic congenital heart defects with intractable hypoplasia of pulmonary arteries.
    Fan XM; Zhu YB; Su JW; Zhang J; Li ZQ; Xu YQ; Li XF; Liu YL
    Chin Med J (Engl); 2013; 126(9):1678-82. PubMed ID: 23652050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prasugrel reduces agonists' inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel.
    Gremmel T; Eslam RB; Koppensteiner R; Lang IM; Panzer S
    Cardiovasc Ther; 2013 Oct; 31(5):e40-5. PubMed ID: 23311679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Point-of-care assessment of platelet aggregation in paediatric open heart surgery.
    Hofer A; Kozek-Langenecker S; Schaden E; Panholzer M; Gombotz H
    Br J Anaesth; 2011 Oct; 107(4):587-92. PubMed ID: 21697184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet hyperreactivity after coronary artery bypass grafting: the possible relevance to glycoprotein polymorphisms. A preliminary report.
    Golanski J; Golanski R; Chizynski K; Iwaszkiewicz A; Rozalski M; Wieclawska B; Boncler M; Watala C
    Platelets; 2001 Jun; 12(4):241-7. PubMed ID: 11454259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neonatal platelets are less reactive than adult platelets to physiological agonists in whole blood.
    Rajasekhar D; Kestin AS; Bednarek FJ; Ellis PA; Barnard MR; Michelson AD
    Thromb Haemost; 1994 Dec; 72(6):957-63. PubMed ID: 7740470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long-term patency after the Blalock-Taussig operation--comparison between classic and modified shunts].
    Ohuchi H; Okabe H; Nagata N; Koseni K; Kaneko Y; Itoh K
    Nihon Kyobu Geka Gakkai Zasshi; 1996 Aug; 44(8):1108-13. PubMed ID: 8828367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modified Blalock-Taussig shunt: immediate and short-term follow-up results in neonates.
    Ahmad U; Fatimi SH; Naqvi I; Atiq M; Moizuddin SS; Sheikh KB; Shahbuddin S; Naseem TM; Javed MA
    Heart Lung Circ; 2008 Feb; 17(1):54-8. PubMed ID: 17683985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists.
    Michelson AD; Furman MI; Goldschmidt-Clermont P; Mascelli MA; Hendrix C; Coleman L; Hamlington J; Barnard MR; Kickler T; Christie DJ; Kundu S; Bray PF
    Circulation; 2000 Mar; 101(9):1013-8. PubMed ID: 10704169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different Effects of Ranibizumab and Bevacizumab on Platelet Activation Profile.
    Sobolewska B; Grimmel C; Gatsiou A; Sopova K; Klein J; Biedermann T; Stellos K; Ziemssen F
    Ophthalmologica; 2015; 234(4):195-210. PubMed ID: 26305017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High haematocrit in cyanotic congenital heart disease affects how fibrinogen activity is determined by rotational thromboelastometry.
    Westbury SK; Lee K; Reilly-Stitt C; Tulloh R; Mumford AD
    Thromb Res; 2013 Aug; 132(2):e145-51. PubMed ID: 23906940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutrophil activation and morbidity in young adults with cyanotic congenital heart disease.
    McLeod KA; Martin P; Williams G; Walker DR
    Blood Coagul Fibrinolysis; 1994 Feb; 5(1):17-22. PubMed ID: 8180336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of diabetes on platelet activation in different manifestations of atherosclerosis.
    Gremmel T; Kopp CW; Seidinger D; Koppensteiner R; Steiner S; Panzer S
    Swiss Med Wkly; 2013; 143():w13800. PubMed ID: 23740526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.